

Co-targeting of HER2/erbB2 and IGF-1R in breast cancer

Anne Camirand¹, Yuhong Lu¹, Michael Pollak¹

Department of Oncology, McGill University, Montreal, QC, Canada

1: Streams of Excellence program of the Canadian Breast Cancer Research Institute.

Summary

Background: The humanized anti-HER2 monoclonal antibody trastuzumab (Herceptin®) is useful in the treatment of ErbB2-overexpressing breast cancers, but its efficiency is limited because development of resistance is common. In order to study the possibility of improving the efficacy of therapies directed against HER2/erbB2, we investigated the effects of co-targeting this receptor and the insulin-like growth factor 1 receptor (IGF-1R), a widely-expressed protein tyrosine kinase with important roles in suppression of apoptosis and stimulation of proliferation.

Material / Methods: The experimental strategy involved combining trastuzumab treatment and reduction of IGF-1R signaling through incremental heat-induced expression of the dominant-negative IGF-1 receptor 486/STOP under the control of the heat-sensitive *Drosophila* HSP70 promoter, in HER2/erbB2-overexpressing MCF7her18 breast cancer cells.

Results: Isobologram analysis of combinatorial treatment data revealed a strong synergistic interaction between trastuzumab treatment and the induction of the dominant-negative IGF-1R expression, resulting in potentiation of growth inhibition in transfected cancer cells.

Conclusions: These observations support the concept that simultaneously co-targeting tyrosine kinase receptors may be therapeutically useful, and provide a specific rationale for combining IGF-1R and HER2/erbB2 targeting strategies in anti-neoplastic approaches.

key words: IGF-1R • HER2/ErbB2 • Trastuzumab • Herceptin • co-targeting • synergy

Abbreviations: EGFR – epidermal growth factor receptor; HER2/ErbB2 – human erbB-related/erythroblastosis virus gene B; IGF-1R – insulin-like growth factor-1 receptor; MAPK – mitogen-activated protein kinase; PI-3K – phosphatidylinositol 3-kinase; PTK – protein tyrosine kinase; RT – reverse transcriptase

Word count: 2112

BACKGROUND

A promising field of oncological study has been opened by the elucidation of the crucial role of protein tyrosine kinases (PTKs) in signal transduction, and by the discovery that PTK signalling is frequently abnormal in cancer. Many novel approaches in antineoplastic therapy take aim at PTK functions [1], and one receptor in particular, HER2/erbB2 (also known as EGFR2 or *neu*) is an excellent clinical target because its frequent overexpression in several types of cancer is associated with poor prognosis [2]. In contrast to other members of the EGFR family, HER2/erbB2 does not seem to possess its own high-affinity ligand, but forms with other ligand-bound other ypeeef-daD1Pve1ypeeef-dhetr G6D7KS;1ligan1poorG1erodimher G606D7C1which G606D7C1se-PSPD06D7C1grow

\$)* (;
5 *D8) *! (8 #
45*2 (, & &) , !
5 5 7
)+(, 3#2 !% (!%
& " >, -:
45*2 (, +,-%. /0 #

! & ! # 1
! ! ! &
! " ! < "
:=# 1 ! &
K.#1#. &
! & & 8H/G8 #
3#3> ! #

' 5 *

8 ! ! & &
! &
& .! < (=# " (# F
@>F &
& " & " & -F
& # 1 &
& # 1 !
5 &
! !
&
1 8 & 3#3 F "
!# 45*2 (,
! &
& ! !#

!"

8 45*2 (, &
) , &
)+(, 45*2 (, +,-%. /0 & & 05
\$)* (*D8)
! 1H8 & # 05
& :J \$)* (>J *D8)
H8

& ! ! & !
(323 &
) , 1H8! \$)* (
3 >J))8)5))) 5 588 88 5
:J" *D8) & (
>J5) 5) 5 8 5) 5 5) 8 :J# 0
45*2 (, +,-%. /0 -:
& ! & + "
H8 & H8
" * & " #
&
!(# 4 H8" ! 4 4DG
\$ G ! (:2E5# 05
& (%(3
& \$)* (*D8)
05 & !
@+E5 :3 " ! >2E5 :3 " !
2 E5 (#> " :> " & (3
! 2 E5# *D8) :J
" & \$)* (; "
+,-%. /0 &
(323 #

\$ & &
+,-%. /0 &
< =# " \$5 >3 &
& ! "
! - !
& ;
\$ &
! ## & "
! ! !

! :@#>E5 #*! : &
!! +
! & :@#>E5 " &
! & :2E5 2 " &
! & # &
! ! !
! !
\$)* (+,-%./0" & !
! "

mutant product capable of inhibiting the wild-type protein function, i.e. a dominant-negative. In this study, a truncated IGF-1R dominant-negative construct (486/STOP) under the control of the *Drosophila* HSP70 heat-sensitive promoter [20] was used for controlled reduction of IGF-1R signalling. Expression of the 486/STOP shortened protein has been shown to decrease autophosphorylation of endogenous IGF-1 receptors in transfected cells, and is known to cause a blockage of cell proliferation [26,27]. Heat-dependent effects on cell growth in the absence of the 486/STOP construct are negligible in the conditions used here as shown by parental cell controls, and the complete growth inhibition observed at 39.5°C in all MCF7her18-486/STOP lines tested is therefore related to IGF-1R dominant-negative interference with cell metabolism. The use of heat shocks of various durations to incrementally induce the expression of genes under the control of heat-sensitive promoters has been reported before [28,29], and this property is used here to allow the design of a combinatorial protocol for isobologram analysis [24,25] which reveals a strong synergistic interaction between trastuzumab treatment and 486/STOP expression. Other synergistic interactions with trastuzumab have been observed for drugs such as cisplatin, docetaxel, thiotepa, and etoposide [30], but this is the first report of synergistic inhibition of growth through interference with the HER2/ErbB2 and IGF-1R signaling pathways. In this type of study, a simple additivity pattern would imply that the agents are acting independently on different metabolic pathways, while synergy (potentiation of one agent on the action of another) suggests the existence of interactions between the pathways targeted. Trastuzumab allows p27^{kip1} expression and facilitates its release from sequestering proteins; it also decreases the levels of cyclin E and of early and mid G1 cyclins, resulting in accumulation of cells in G1 phase [4,5]. IGF-1 has been demonstrated in MCF7 cells to increase cyclin D1 and 5 expression, and to post-transcriptionally decrease p27^{kip1} levels, all of which facilitate passage from G1 to S phase [31]. Signaling pathways for HER2/ErbB2 and IGF-1R have been shown to cross-talk [32], and unpublished results from our laboratory suggest that IGF-1 antagonism to trastuzumab is effected through the targeting of p27^{kip1} to the proteasome degradation machinery (Lu et al, unpublished). It is therefore likely that the synergistic action of trastuzumab and 486/STOP treatments involves potentiation of this cell cycle control step towards the significant growth inhibition observed in this study.

CONCLUSIONS

Our results represent the first report of formal isobologram analysis for evaluating antagonism, additivity or synergy between treatments targeting two tyrosine kinase receptors. The finding of synergy confirms that there are benefits to co-targeting approaches, and more specifically, that the antineoplastic effects of blocking tyrosine kinase receptors of the EGF family may be enhanced by co-targeting IGF-1R.

Acknowledgements

We thank Dr. Renato Baserga (Jefferson Cancer Center, Thomas Jefferson University, Philadelphia, USA) for the pGR228 plasmid, and Dr. Moulay Alaoui-Jamali, Lady Davis Institute, McGill University, Montreal, Quebec, Canada, for the human breast cancer MCF7 cells overexpressing the HER2/erbB2 receptor (MCF7her18).

REFERENCES:

1. Sawyers CL: Rational therapeutic intervention in cancer: kinases as drug targets. *Curr Opin Genet Dev*, 2002; 1: 111-115
2. Hung MC, Lau YK: Basic science of HER2/neu: a review. *Seminars in Oncol*, 1999; 26(4) suppl. 12: 51-59
3. Kraus MH, Popescu NC, Amsbaugh SC, King CR: Overexpression of the EGF receptor related proto-oncogene erbB2 in human mammary tumor cell lines by different molecular mechanisms. *EMBO J*, 1987; 6: 605-610
4. Harari D, Yarden Y: Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. *Oncogene*, 2000; 19: 6102-6114
5. Baselga J, Albanell J: Mechanism of action of anti-HER2 monoclonal antibodies. *Annals of Oncol*, 2001; 12 (suppl. 1): S35-S41
6. Le XF, McWatters A, Wiener J et al: Anti-HER2 antibody and heregulin suppress growth of HER2-overexpressing human breast cancer cells through different mechanisms. *Clin Cancer Res*, 2000; 6: 260-270
7. Clynes RA, Towers TL, Presta LG, Ravetch JV: Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. *Nature Med*, 2000; 6: 443-446
8. Albanell J, Baselga J: Unraveling resistance to trastuzumab (Herceptin): insulin-like growth factor-1 receptor, a new suspect. *J Natl Cancer Inst*, 2001; 93: 1830-1832
9. Ye D, Mendelsohn J, Fan Z: Androgen and epidermal growth factor down-regulate cyclin-dependent kinase inhibitor p27^{kip1} and costimulate proliferation of MDA Pca 2a and MDA Pca 2b prostate cancer cells. *Clin Cancer Res*, 1999; 5: 2171-2177
10. Lu YH, Zi X, Zhao Y et al: Insulin-like growth factor 1 receptor signaling and resistance to Trastuzumab (Herceptin). *J Nat Cancer Inst*, 2001; 93: 1852-1857
11. Moasser MM, Basso A, Averbuch SD, Rosen N: The tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. *Cancer Res*, 2001; 61: 7184-7188
12. Moulder SL, Yakes FM, Muthuswamy SK et al: Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. *Cancer Res*, 2001; 61: 8887-8895
13. Chakravarti A, Loeffler JS, Dyson NJ: Insulin-like growth factor receptor-1 mediates resistance to anti-epidermal growth factor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. *Cancer Res*, 2002; 61: 200-207
14. Totpal K, Lewis Phillips GD, Balter I, Sliwkowski MX: Augmentation of rhuMAb2C4-induced growth inhibition by Tarceva the EGFR tyrosine kinase inhibitor on human breast cancer cell lines. *Proc Am Assoc Cancer Res*, 2002; 43: 3889
15. Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE: The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. *Endocrine Rev*, 2000; 21: 215-244
16. Reiss K, D'Ambrosio C, Tu X et al: Inhibition of tumour growth by a dominant-negative mutant of the insulin-like growth factor 1 receptor with a bystander effect. *Clin Cancer Res*, 1998; 4: 2647-2655
17. Arteaga CL, Kitten LJ, Coronado EB et al: Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. *J Clin Invest*, 1989; 84: 1418-1423
18. Andrews DW, Resnicoff M, Flanders AE et al: Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type 1 receptor in malignant astrocytomas. *J Clin Oncol*, 2001; 19: 2189-2200

19. Baserga R, Morrione A: Differentiation and malignant transformation: two roads diverged in a wood. *J Cellular Biochem*, 1999; Suppl. 32/33: 68-75
20. Romano G, Reiss K, Tu X et al: Efficient in vitro and in vivo gene regulation of a retrovirally delivered pro-apoptotic factor under the control of the *Drosophila* HSP70 promoter. *Gene Ther*, 2001; 8: 600-607
21. Gatzka M, Prisco M, Baserga R: Stabilization of the ras oncoprotein by the insulin-like growth factor 1 receptor during anchorage-independent growth. *Cancer Res*, 2000; 60: 4222-4230
22. Berenbaum M: Criteria for analyzing interactions between biologically active agents. *Adv Cancer Res*, 1981; 35: 269-335
23. Gessner PK: Isobolographic analysis of interactions: an update on applications and utility. *Toxicology*, 1995; 105: 161-179
24. Valentinis B, Morrione A, Peruzzi F et al: Anti-apoptotic signaling of the IGF-1 receptor in fibroblasts following loss of matrix adhesion. *Oncogene*, 1999; 18: 1827-1836
25. Baserga R: The price of independence. *Exp Cell Res*, 1997; 236: 1-3
26. D'Ambrosio C, Ferber A, Resnicoff M, Baserga RA: A soluble insulin-like growth factor-1 receptor that induces apoptosis of tumor cells in vivo and inhibits tumorigenesis. *Cancer Res*, 1996; 56: 4013-4020
27. Reiss K, Tu X, Romano G et al: Intracellular association of a mutant insulin-like growth factor receptor with endogenous receptors. *Clin Cancer Res*, 2001; 7: 2134-2144
28. Luna MC, Ferrario A, Wong S et al: Photodynamic therapy-mediated oxidative stress as a molecular switch for the temporal expression of genes ligated to the human heat shock promoter. *Cancer Res*, 2000; 60: 1637-1644
29. BDCmnSCMemote7r; Sgeeny DMg S et Al: PhotoHeC
28. RomanPeic maserHsu S, Lewed oxtriHc I/neuinhtibmicinhib 19opy-euignas. *Adv us*

